{"id":516703,"date":"2021-07-22T16:09:31","date_gmt":"2021-07-22T20:09:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/"},"modified":"2021-07-22T16:09:31","modified_gmt":"2021-07-22T20:09:31","slug":"eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/","title":{"rendered":"Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">&#8211;  Live Conference Call and Webcast at 4:30 PM ET  &#8211;<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">PALO ALTO, Calif.<\/span>, <span class=\"xn-chron\">July 22, 2021<\/span> \/PRNewswire\/ &#8212; Eiger BioPharmaceuticals, Inc.\u00a0(Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call on\u00a0Thursday, August 5, 2021\u00a0at\u00a04:30 PM ET to discuss its financial results and provide a business update for the second quarter 2021.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg\" title=\"Eiger BioPharmaceuticals (PRNewsFoto\/Eiger BioPharmaceuticals, Inc.)\" alt=\"Eiger BioPharmaceuticals (PRNewsFoto\/Eiger BioPharmaceuticals, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The live and replayed webcast of the call will be available through the company&#8217;s website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3236964-1&amp;h=1435227949&amp;u=http%3A%2F%2Fwww.eigerbio.com%2F&amp;a=www.eigerbio.com\" rel=\"nofollow noopener\">www.eigerbio.com<\/a>.\u00a0To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 9482721.\u00a0The webcast will be archived and available for replay for at least 90 days after the event.<\/p>\n<p>\n        <b>About Eiger<br \/><\/b>Eiger\u00a0is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.<\/p>\n<p>Eiger&#8217;s\u00a0lead clinical programs are focused on the development of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of viral hepatitis, with two complementary HDV treatments. Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon lambda is a first-in-class, type III, well-tolerated interferon entering Phase 3.<\/p>\n<p>Zokinvy<sup>\u00ae<\/sup>\u00a0for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company&#8217;s first FDA approved product. A Marketing Authorization Application (MAA) is under review by the\u00a0European Medicines Agency\u00a0(EMA).<\/p>\n<p>For additional information about\u00a0Eiger\u00a0and its clinical programs, please visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3236964-1&amp;h=1435227949&amp;u=http%3A%2F%2Fwww.eigerbio.com%2F&amp;a=www.eigerbio.com\" rel=\"nofollow noopener\">www.eigerbio.com<\/a>.<\/p>\n<p>SOURCE Eiger BioPharmaceuticals, Inc. <\/p>\n<p>Investors and Media:<br \/>Charles Butler\u00a0<br \/>VP, Investor Relations and Corporate Communications<br \/>Email:\u00a0<a target=\"_blank\" href=\"mailto:cbutler@eigerbio.com\" rel=\"nofollow noopener\">cbutler@eigerbio.com<\/a><br \/>Phone: 1-650-272-6138<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE52277&amp;sd=2021-07-22\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5-301339797.html\">https:\/\/www.prnewswire.com\/news-releases\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5-301339797.html<\/a><\/p>\n<p>SOURCE  Eiger BioPharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE52277&amp;Transmission_Id=202107221605PR_NEWS_USPR_____NE52277&amp;DateId=20210722\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Live Conference Call and Webcast at 4:30 PM ET &#8211; PR Newswire PALO ALTO, Calif., July 22, 2021 \/PRNewswire\/ &#8212; Eiger BioPharmaceuticals, Inc.\u00a0(Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call on\u00a0Thursday, August 5, 2021\u00a0at\u00a04:30 PM ET to discuss its financial results and provide a business update for the second quarter 2021. The live and replayed webcast of the call will be available through the company&#8217;s website at www.eigerbio.com.\u00a0To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 9482721.\u00a0The webcast will be archived and available for replay for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-516703","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; Live Conference Call and Webcast at 4:30 PM ET &#8211; PR Newswire PALO ALTO, Calif., July 22, 2021 \/PRNewswire\/ &#8212; Eiger BioPharmaceuticals, Inc.\u00a0(Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call on\u00a0Thursday, August 5, 2021\u00a0at\u00a04:30 PM ET to discuss its financial results and provide a business update for the second quarter 2021. The live and replayed webcast of the call will be available through the company&#8217;s website at www.eigerbio.com.\u00a0To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 9482721.\u00a0The webcast will be archived and available for replay for &hellip; Continue reading &quot;Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-22T20:09:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5\",\"datePublished\":\"2021-07-22T20:09:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\\\/\"},\"wordCount\":309,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/285009\\\/eiger_biopharmaceuticals_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\\\/\",\"name\":\"Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/285009\\\/eiger_biopharmaceuticals_logo.jpg\",\"datePublished\":\"2021-07-22T20:09:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/285009\\\/eiger_biopharmaceuticals_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/285009\\\/eiger_biopharmaceuticals_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/","og_locale":"en_US","og_type":"article","og_title":"Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5 - Market Newsdesk","og_description":"&#8211; Live Conference Call and Webcast at 4:30 PM ET &#8211; PR Newswire PALO ALTO, Calif., July 22, 2021 \/PRNewswire\/ &#8212; Eiger BioPharmaceuticals, Inc.\u00a0(Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call on\u00a0Thursday, August 5, 2021\u00a0at\u00a04:30 PM ET to discuss its financial results and provide a business update for the second quarter 2021. The live and replayed webcast of the call will be available through the company&#8217;s website at www.eigerbio.com.\u00a0To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 9482721.\u00a0The webcast will be archived and available for replay for &hellip; Continue reading \"Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-22T20:09:31+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5","datePublished":"2021-07-22T20:09:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/"},"wordCount":309,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/","name":"Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg","datePublished":"2021-07-22T20:09:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-to-host-conference-call-for-second-quarter-2021-financial-results-and-business-update-on-thursday-august-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=516703"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516703\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=516703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=516703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=516703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}